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Abstract 
Background: Despite the research importance of rhinovirus detection in asymptomatic healthy infants, the literature 
remains sparse.
Objective: To investigate the prevalence of respiratory syncytial virus (RSV) and rhinovirus (and its species).
Methods: We conducted a cross-sectional study of 110 healthy, non-hospitalized infants without acute illness at an 
academic medical center from November 2013 through May 2014. We tested nasal swab specimens by using poly-
merase chain reaction and genetic sequencing.
Results: Overall, the median age was 3.8 months (IQR 2.0–5.1 months), 56 % were male, and 90 % were 
born >37 weeks. RSV was detected in nasal swabs from infants (1.8 %). By contrast, rhinovirus was detected in nasal 
swabs from 16 infants (14.5 %). Molecular typing assay revealed rhinovirus species: six rhinovirus-A (5.5 %), one 
rhinovirus-B (0.9 %), eight rhinovirus-C (7.3 %), and one untypeable (0.9 %).
Conclusions: In this cross-sectional study of healthy, community-based infants, RSV was rare (<2 %) in nasal swabs, 
while rhinovirus was detected in 14.5 % with a predominance of rhinovirus-A and -C. These finding are important for 
understanding the clinical significance of rhinovirus detection among infants hospitalized for bronchiolitis.
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Background
Respiratory syncytial virus (RSV) and rhinovirus are the 
most frequently detected viral pathogens in infants with 
bronchiolitis, a leading cause of emergency department 
visit [1, 2] and hospitalization for United States infants 
[3]. Although it has long been the conventional wisdom 
that the infectious etiology of bronchiolitis does not 
affect outcomes, a growing number of studies have linked 
viral pathogens of bronchiolitis (e.g., rhinovirus) to 
long-term respiratory outcomes [4]. For example, stud-
ies reported that RSV bronchiolitis in infancy, especially 
when severe (e.g., requiring hospitalization) contribute 
to subsequent development of childhood asthma, while 
more recent research has focused on the potential role of 
rhinovirus bronchiolitis, particularly rhinovirus species 
C, in early life in asthma pathogenesis [4].
A causal role of RSV and rhinovirus in lower respira-
tory infection is supported by isolation of viruses from 
the respiratory tract of children. However, advances in 
viral detection techniques (e.g., polymerase chain reac-
tion [PCR] testing) have enabled increased identifica-
tion of RSV and rhinovirus, not only in infants with 
acute respiratory infection (ARI) but also in asympto-
matic individuals [5, 6]. A systematic review reported, 
in the respiratory samples of asymptomatic individuals 
(all ages), a mean viral prevalence of 2.6 % for RSV and 
15.1 % for rhinovirus [5]. This finding questions the clini-
cal significance of rhinovirus detection in young children 
with bronchiolitis. However, only a few studies, with 
small sample sizes, have specifically examined commu-
nity-based infants (aged < 1 year) without comorbidities 
and without a high risk for atopy [7, 8]. Additionally, the 
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prevalence of different rhinovirus species in this popula-
tion remains largely unclear. To address these knowledge 
gaps, we investigated the prevalence of RSV and rhinovi-
rus (and its species) by using PCR and molecular typing 
assay on nasal swab specimens from healthy, non-hospi-
talized infants without acute illness.
Methods
Study design and participants
We conducted a cross-sectional study of healthy infants 
enrolled from a primary care group practice at Massa-
chusetts General Hospital (Boston, Massachusetts) from 
November 2013 through May 2014. Inclusion criteria 
were infants aged < 1 year and gestational age > 34 weeks. 
In the 3 days before a scheduled clinic visit, families were 
screened via phone to determine interest and eligibility. 
Exclusion criteria included comorbidities (heart–lung 
disease, immunodeficiency, immunosuppression, or 
chronic gastrointestinal disorder); previous lower respira-
tory infection that resulted in an urgent clinic visit, emer-
gency department visit, or hospitalization; any diarrheal 
illness lasting >24 h in the past week; any treatment with 
antibiotics in the past week; and current fever, ARI, or 
gastrointestinal illness. We defined current ARI and gas-
trointestinal illness based on the literature [9]. ARI was 
defined as two of the following symptoms for 1  day, or 
one of the following symptoms for two consecutive days: 
runny nose, stuffy or blocked nose, cough, fever, sore 
throat, or sneezing. Gastrointestinal illness was defined 
as: two or more looser than normal stools or any vomit-
ing within 24 h. The institutional review board of Massa-
chusetts General Hospital approved the study. Informed 
consent was obtained from the parents or guardians.
Data and sample collection
Clinical data were collected from parents via struc-
tured interview and from medical record review. Data 
included infants’ demographic characteristics as well as 
medical, environmental, and family history. Nasal swabs 
were collected from the anterior nares using a standard-
ized protocol. Both nares were swabbed with a single 
nylon, pediatric FLOQSwab (Copan, Brescia, Italy). The 
swab was then added to 2 mL of viral transport medium 
and frozen at −80  °C. Samples were shipped on dry ice 
to the laboratory at Baylor College of Medicine, where 
they were stored at −80 °C. Samples were extracted and 
cDNA was generated using random hexamers for RSV 
and gene specific primers for rhinovirus. Singleplex 
and duplex real time PCR were used to detect rhinovi-
rus and RSV respectively. Details of rhinovirus prim-
ers and probes have been described elsewhere [10], and 
sequences of RSV primers and probes are available upon 
request. Next, rhinovirus-positive specimens were sent 
to University of Wisconsin. Rhinovirus species were 
identified by using molecular typing assay that targets a 
variable fragment in 5′ untranslated region of the viral 
genome flanked by highly conserved motifs [11].
Statistical analyses
All analyses were performed using Stata SE 13.1 software 
(Stata Corp, College Station, TX). Patient demographic 
and clinical characteristics were compared by rhinovirus 
status, using Mann–Whitney, Chi Square, or Fisher exact 
tests, as appropriate.
Results
Table  1 summarizes demographic and clinical charac-
teristics of the 110 enrolled infants. Overall, the median 
age was 3.8  months (IQR 2.0–5.1  months), 56  % were 
male, 51  % were non-Hispanic white, and 90  % were 
born >37 weeks.
RSV was detected in nasal swabs from only two 
infants (1.8  %). By contrast, rhinovirus was detected 
in nasal swabs from 16 infants (14.5  %) with a median 
cycle threshold value of 29 (IQR 26–34). Molecular 
typing assay revealed rhinovirus species: six rhinovi-
rus-A (5.5  %), one rhinovirus-B (0.9  %), eight rhinovi-
rus-C (7.3  %), and one untypeable (0.9  %). Infants with 
detected rhinovirus were older than those without (4.3 
vs. 2.6 months; P = 0.03), and were more likely to attend 
daycare (43.8 vs. 9.6 %; P = 0.002) and be exposed to pas-
sive smoke in home (12.5 vs. 2.1 %; P = 0.04). There were 
no other significant differences in demographic or clini-
cal characteristics between the two groups (Table 1).
In a sensitivity analysis, we limited our analysis to 
infants who were completely symptom-free at the time of 
the screening phone call and enrollment. In this subset 
of 96 infants, RSV was detected in one infant (1.0 %) and 
rhinovirus in 11 (11.5 %). Molecular typing assay revealed 
six rhinovirus-A (6.3  %), no rhinovirus-B, four rhinovi-
rus-C (4.2 %), and one untypeable (1.1 %).
Discussion
In this study of 110 healthy, community-based infants, 
RSV was rarely detected (1.8 %). By contrast, rhinovirus 
was detected in the nasal swab specimens from 14.5 % of 
healthy infants, with predominance of rhinovirus-A and 
-C. When limiting our analysis to those who were com-
pletely asymptomatic at screening and enrollment, the 
rhinovirus prevalence decreased to 11.5 %.
Despite the research importance of rhinovirus (over-
all and species) detection in asymptomatic “healthy” 
infants, the literature remains sparse [12, 13]. Our rhino-
virus findings are in agreement with a prior U.S. study on 
asymptomatic infants (0–5 months), which found overall 
rhinovirus prevalence of 11.4 % with a rhinovirus-A and 
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-C predominance (rhinovirus-A 7.0 %, rhinovirus-B 0 %, 
and rhinovirus-C 4.4 %) [12]. However, the earlier study 
differed by including children with comorbidities such as 
wheezing, chronic heart–lung disease, and immunodefi-
ciency. In addition, other community-based studies were 
conducted among infants at high risk for atopy, includ-
ing a Dutch study that used nasal brush specimens and 
found a rhinovirus prevalence of 17  % among 6  month 
old asymptomatic infants, the majority of whom had a 
parent with allergic disease [5]. Likewise, in the Child-
hood Origins of Asthma study, the rhinovirus prevalence 
was 32  % using nasal washes among infants  <1  year, all 
of whom were at high risk for atopy [5]. Additional stud-
ies among healthy, community-based infants age <1 year 
using nasopharyngeal swabs or nasal washes reported 
rhinovirus prevalence of 12–24  %, but based on small 
samples (n < 35 subjects) [7, 8]. A major strength of our 
study, compared to previous research, is assessing viral 
prevalence and rhinovirus species in a young population 
(median age 3.8 months, comparable to the median age 
of bronchiolitis hospitalization [4]) without comorbidi-
ties or high-risk of atopy.
Interestingly, we found that the rhinovirus genomic load 
among infants with rhinovirus detection was intermediate 
[14]. The mechanisms of rhinovirus positivity are unclear 
and likely multifactorial—e.g., active replication without 
respiratory symptoms, prolonged viral shedding, delayed 
clearance, and combinations of these factors in the popu-
lation. The observed difference in patient characteristics 
(e.g. a higher rate of day care attendance and exposure 
to passive smoke in home among infants with rhinovirus 
detection) may paly a role in these potential mechanisms. 
The significance and mechanisms of rhinovirus detection 
in asymptomatic children merit further investigation.
Our finding of low RSV prevalence in asymptomatic 
infants suggests that RSV is likely the causative agent 
Table 1 Demographic and clinical characteristics of 110 healthy infants
Data were expressed as numbers (percentages) unless otherwise indicated
Characteristics All infants  
(n = 110)
Rhinovirus positive  
(n = 16)




Age in months, median (IQR) 3.8 (2.0–5.1) 4.3 (3.6–5.8) 2.6 (1.9–4.5) 0.03
Sex 0.60
 Male 62 (56) 10 (63) 52 (55)
 Female 48 (44) 6 (38) 42 (45)
Race/ethnicity 0.80
 Non-hispanic white 56 (51) 10 (63) 46 (49)
 Non-hispanic black 11 (10) 1 (6) 10 (11)
 Hispanic 20 (18) 3 (19) 17 (18)
 Other 23 (21) 2 (13) 21 (22)
Insurance 0.30
 Private 89 (81) 15 (94) 74 (79)
 Public 21 (19) 1 (6) 20 (21)
Home environment characteristics
Sibling in home 47 (43) 7 (44) 40 (43) 0.93
Day care attendance 16 (15) 7 (44) 9 (10) 0.002
Exposure to passive smoke in home 4 (4) 2 (13) 2 (2) 0.04
Clinical characteristics
Gestational age 0.30
 ≥40 weeks 46 (42) 4 (25) 42 (45)
 38–39 weeks 53 (48) 10 (63) 43 (46)
 34–37 weeks 11 (10) 2 (13) 9 (10)
Delivery mode 0.92
 Vaginal delivery 70 (64) 10 (63) 60 (64)
 Cesarean section 40 (36) 6 (38) 34 (36)
Primarily breast milk feeding from ages 0 to  
3 months
84 (76) 12 (75) 72 (77) 0.99
Eczema 17 (15) 4 (25) 13 (14) 0.27
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when detected in the setting of clinical symptoms of 
bronchiolitis. By contrast, given the observed prevalence 
of rhinovirus in infants without ARI, and even in infants 
without any respiratory symptoms, it remains unclear if 
rhinovirus detection always reflects current illness. Rhi-
novirus is frequently detected in the setting of multiple 
coexisting viruses [4]. Although a recent study of healthy 
infants showed that persistence of rhinovirus genome 
beyond 30 days was uncommon, 8.9 % of distinct rhinovi-
rus infections lasted longer than 14 days, and 4.5 % lasted 
longer than 30 days [15]. Thus, while rhinovirus detected 
during bronchiolitis hospitalization can have an etiologic 
role, an alternate scenario is that the detected rhinovi-
rus is persistent from a previous infection, and perhaps 
a marker of subject susceptibility or impaired immune 
response to rhinovirus infection. The generally higher 
rhinovirus prevalence found in studies of asymptomatic 
infants at high risk for atopy [5] may support this theory.
Our study has several potential limitations. First, the 
sample size, although larger than several prior studies, 
remains relatively small and all infants were recruited 
from one group practice in Boston, which may limit our 
generalizability to other settings. Second, this study was 
a single-year study; therefore, it is possible that an out-
break of a less virulent strain of rhinovirus occurred 
during this study period. Additionally, specimens were 
collected from late fall to early spring, yet rhinovirus 
infections occur year-round. While the observed preva-
lence could be different in months we did not enroll sub-
jects, this chosen study period is helpful for bronchiolitis 
researchers. Third, ours study did not test other respira-
tory viruses, such as adenovirus, coronavirus, and human 
metapneumovirus. However, RSV and rhinoviruses are 
the most frequently detected respiratory viruses in young 
children (e.g., 85 % in children hospitalized for bronchi-
olitis [4]). Lastly, this cross-sectional study did not follow 
up the infants after enrollment to determine if some went 
on to develop ARI in the days after sample collection. 
Nevertheless, our results add to a surprisingly sparse 
literature and will aid interpretation of studies on viral 
bronchiolitis.
Conclusions
In summary, in this cross-sectional study of healthy, 
community-based infants age  <  1  year without ARI or 
comorbidities, RSV was rare (<2 %) in nasal swabs, while 
rhinovirus was detected in 11–15 % with a predominance 
of rhinovirus-A and -C. These finding are important 
for understanding the clinical significance of rhinovirus 
detection among infants hospitalized for bronchioli-
tis. To help tease out the role of rhinovirus detection in 
severe bronchiolitis and asthma pathogenesis, we plan to 
pursue future studies comparing rhinovirus prevalence, 
including genotyping, between infants hospitalized 
for severe bronchiolitis and healthy, community-based 
controls.
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